Active safety monitoring of the mRNA Pfizer-Biontech (Comirnaty) vaccine using a recipient survey: a New Zealand first.
- At: Seville (Spain) (2022)
- Type: Poster
- Poster code: RSC-004
- By: HANLON, Timothy (Ministry of Health New Zealand, New Zealand)
- Co-author(s): Dr Timothy Hanlon, Group Manager (Ministry of Health New Zealand, Wellington, New Zealand)
Ms Mariana Traslosheros Reyes, Advisor (Ministry of Health New Zealand, Wellington, New Zealand)
Ms Muireann Walton, Senior Advisor (Ministry of Health New Zealand, Wellington, New Zealand)
Background information: New Zealand began vaccinating its population with the mRNA Pfizer-BioNTech (Comirnaty) vaccine in February 2021. Although Comirnaty demonstrated good efficacy and safety in phase III clinical trials, post-marketing surveillance is needed to understand its safety in the real-world, especially in New Zealand due to its unique .. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.